About: Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes
Creator	Cano-Garrido, Olivia Garcia-Fruitós, Elena Seras-Franzoso, Joaquin
Source	Medline; PMC
abstract	Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram-positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
has issue date	2015-09-16(xsd:dateTime)
bibo:doi	10.1186/s12934-015-0313-6
bibo:pmid	26377321
has license	cc-by
sha1sum (hex)	427c25eb5418afb2f27b6f27b6c7c07b4ea7af08
schema:url	https://doi.org/10.1186/s12934-015-0313-6
resource representing a document's title	Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes
has PubMed Central identifier	PMC4573465
has PubMed identifier	26377321
schema:publication	Microb Cell Fact
resource representing a document's body	covid:427c25eb5418afb2f27b6f27b6c7c07b4ea7af08#body_text
is schema:about of	named entity 'LIVE' named entity 'species' named entity 'diabetes' named entity 'cancer' named entity 'functional' named entity 'exploitation' named entity 'Food' named entity 'engineered' named entity 'RECOMBINANT PROTEINS' named entity 'GENETICALLY MODIFIED ORGANISMS' named entity 'CELL' named entity 'NEED' named entity 'COST' named entity 'PROBIOTIC' named entity 'OVERVIEW' named entity 'CAPABLE' named entity 'ROLE' named entity 'AIMS' named entity 'BACTERIA ' named entity 'MOLECULES' named entity 'GIVEN' named entity 'FUNCTIONAL' named entity 'WHERE' named entity 'PLAY' named entity 'FAR' named entity 'REVIEW' named entity 'INCLUDING' named entity 'ADMINISTRATION' named entity 'GASTROINTESTINAL TRACT' named entity 'DELIVER' named entity 'STRATEGIES' named entity 'SURVIVE' named entity 'SAFE' named entity 'EFFORT' named entity 'TO PROVIDE' named entity 'HAVE' named entity 'FOOD AND DRUG ADMINISTRATION' named entity 'THESE' named entity 'REACH' named entity 'PROTEINS' named entity 'OF INTEREST' named entity 'HUMAN HEALTH' named entity 'ALTERNATIVE' named entity 'PATHOLOGIES' named entity 'CANCER' named entity 'DIABETES' named entity 'PRODUCE' named entity 'AMPLIFY' named entity 'USED' named entity 'LACTIC ACID BACTERIA' named entity 'IMPORTANT' named entity 'GENERALLY RECOGNIZED AS SAFE' named entity 'PROMOTE' named entity 'USE' named entity 'DIFFERENT' named entity 'ORAL' named entity 'VAGINAL DELIVERY' named entity 'ORGANISMS' named entity 'DELIVERY' named entity 'LONG' named entity 'USE OF' named entity 'TREATMENT' named entity 'INTESTINE' named entity 'PRESERVATION' named entity 'DECREASE' named entity 'BEING' named entity 'CONTEXT' named entity 'OPTION' named entity 'LACTIC ACID BACTERIA' named entity 'POTENTIAL' named entity 'SAFETY' named entity 'VECTOR' named entity 'PURPOSES' named entity 'DELIVERY' named entity 'BIOMEDICAL' named entity 'ENGINEERED' named entity 'VECTORS' named entity 'RANGE' named entity 'DEVELOPMENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software